Please login to the form below

Not currently logged in
Email:
Password:

Almirall launches Solaraze in Spain

Pharma company says move strengthens its dermatology business strategy

Almirall has launched its actinic keratosis treatment Solaraze (diclofenac sodium and hyaluronic acid) in Spain.

Barcelona-based Almirall said the domestic launch of Solaraze consolidates its business strategy in dermatology, which along with respiratory R&D makes up the firm's key research focus.

Through a gel formulation applied twice a day for 90 days Solaraze stimulates the skin's defence system to destroy damaged cells and encourage healthy cells to replace them.

Actinic keratosis is a pre-cancerous lesion that an estimated one in six people will develop at some point in their lives.

Also known as solar keratosis, actinic keratosis appears as a small scaly or rough bump on the skin's surface. It takes years to develop and usually appears on the face, ears or scalp, the neck and back of hands and forearms and on the lips.

The lesions, which are most often caused by exposure to the sun, are not usually life-threatening if they are detected and treated in the early stages.

Solarze was developed by SkyePharma and first marketed by Shire Pharmaceuticals, until Almirall acquired the product, and seven others, in a $213m deal in 2007.

15th December 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics